{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:27:12Z","timestamp":1790720832660,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Circulating tumor cells (CTCs) drive metastasis, the leading cause of death in individuals with breast cancer. Due to their low abundance in the circulation, robust CTC expansion protocols are urgently needed to effectively study disease progression and therapy responses. Here we present the establishment of long-term CTC-derived organoids from female individuals with metastatic breast cancer. Multiomics analysis of CTC-derived organoids along with preclinical modeling with xenografts identified neuregulin 1 (NRG1)\u2013ERBB2 receptor tyrosine kinase 3 (\n                    <jats:italic>ERBB3<\/jats:italic>\n                    \/HER3) signaling as a key pathway required for CTC survival, growth and dissemination. Genome-wide CRISPR activation screens revealed that fibroblast growth factor receptor 1 (FGFR1) signaling serves a compensatory function to the NRG1\u2013HER3 axis and rescues NRG1 deficiency in CTCs. Conversely, NRG1\u2013HER3 activation induced resistance to FGFR1 inhibition, whereas combinatorial blockade impaired CTC growth. The dynamic interplay between NRG1\u2013HER3 and FGFR1 signaling reveals the molecular basis of cancer cell plasticity and clinically relevant strategies to target it. Our CTC organoid platform enables the identification and validation of patient-specific vulnerabilities and represents an innovative tool for precision medicine.\n                  <\/jats:p>","DOI":"10.1038\/s43018-024-00882-2","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:02:14Z","timestamp":1735880534000},"page":"67-85","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Circulating tumor cell plasticity determines breast cancer therapy resistance via neuregulin 1\u2013HER3 signaling"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-6756","authenticated-orcid":false,"given":"Roberto","family":"W\u00fcrth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3541-9170","authenticated-orcid":false,"given":"Elisa","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Michel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-4427","authenticated-orcid":false,"given":"Tasneem","family":"Cheytan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Doncevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenija","family":"Gutjahr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Alborzinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7175-362X","authenticated-orcid":false,"given":"Umut","family":"Yildiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Hlevnjak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Kozyulina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah-Jane","family":"Neuberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1328-9809","authenticated-orcid":false,"given":"Paul","family":"Schwerd-Kleine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-6114","authenticated-orcid":false,"given":"Sevin\u00e7","family":"Jakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-5375","authenticated-orcid":false,"given":"Nicole","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlou Kristina","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid K.","family":"Laut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0695-1854","authenticated-orcid":false,"given":"Darja","family":"Karpova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-5735","authenticated-orcid":false,"given":"Mattia","family":"Falcone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Hardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-8804","authenticated-orcid":false,"given":"Benjamin","family":"Theek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celina V.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Haselmayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7166-5232","authenticated-orcid":false,"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Riethdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-2772","authenticated-orcid":false,"given":"Klaus","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Zapatka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"S\u00fcltmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4989-4722","authenticated-orcid":false,"given":"Carl","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Thewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-7574","authenticated-orcid":false,"given":"Martin R.","family":"Sprick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6212-3466","authenticated-orcid":false,"given":"Andreas","family":"Trumpp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"882_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/nbt.2576","volume":"31","author":"I Baccelli","year":"2013","unstructured":"Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539\u2013544 (2013).","journal-title":"Nat. Biotechnol."},{"key":"882_CR2","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1158\/1078-0432.CCR-15-1603","volume":"22","author":"WJ Janni","year":"2016","unstructured":"Janni, W. J. et al. Pooled analysis of the prognostic relevance of circulating tumor cells in primary breast cancer. Clin. Cancer Res. 22, 2583\u20132593 (2016).","journal-title":"Clin. Cancer Res."},{"key":"882_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabieres","year":"2016","unstructured":"Alix-Panabieres, C. & Pantel, K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 6, 479\u2013491 (2016).","journal-title":"Cancer Discov."},{"key":"882_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","volume":"176","author":"S Gkountela","year":"2019","unstructured":"Gkountela, S. et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell 176, 98\u2013112 (2019).","journal-title":"Cell"},{"key":"882_CR5","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911908","volume":"12","author":"C Koch","year":"2020","unstructured":"Koch, C. et al. Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity. EMBO Mol. Med. 12, e11908 (2020).","journal-title":"EMBO Mol. Med."},{"key":"882_CR6","doi-asserted-by":"publisher","first-page":"180ra148","DOI":"10.1126\/scitranslmed.3005109","volume":"5","author":"L Zhang","year":"2013","unstructured":"Zhang, L. et al. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med. 5, 180ra148 (2013).","journal-title":"Sci. Transl. Med."},{"key":"882_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1126\/science.1253533","volume":"345","author":"M Yu","year":"2014","unstructured":"Yu, M. et al. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345, 216\u2013220 (2014).","journal-title":"Science"},{"key":"882_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/s41416-022-01819-1","volume":"127","author":"SZ Eslami","year":"2022","unstructured":"Eslami, S. Z., Cortes-Hernandez, L. E., Thomas, F., Pantel, K. & Alix-Panabieres, C. Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. Br. J. Cancer 127, 800\u2013810 (2022).","journal-title":"Br. J. Cancer"},{"key":"882_CR9","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1158\/2159-8290.CD-20-1311","volume":"11","author":"C Alix-Panabieres","year":"2021","unstructured":"Alix-Panabieres, C. & Pantel, K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 11, 858\u2013873 (2021).","journal-title":"Cancer Discov."},{"key":"882_CR10","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1126\/science.1228522","volume":"339","author":"M Yu","year":"2013","unstructured":"Yu, M. et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 339, 580\u2013584 (2013).","journal-title":"Science"},{"key":"882_CR11","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A Perez-Gonzalez","year":"2023","unstructured":"Perez-Gonzalez, A., Bevant, K. & Blanpain, C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat. Cancer 4, 1063\u20131082 (2023).","journal-title":"Nat. Cancer"},{"key":"882_CR12","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.3390\/cancers13153693","volume":"13","author":"AM Dujon","year":"2021","unstructured":"Dujon, A. M. et al. Is there one key step in the metastatic cascade? Cancers 13, 3693 (2021).","journal-title":"Cancers"},{"key":"882_CR13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature19328","volume":"537","author":"NV Jordan","year":"2016","unstructured":"Jordan, N. V. et al. HER2 expression identifies dynamic functional states within circulating breast cancer cells. Nature 537, 102\u2013106 (2016).","journal-title":"Nature"},{"key":"882_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00208-2","volume":"7","author":"F Schettini","year":"2021","unstructured":"Schettini, F. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer 7, 1 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"882_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med."},{"key":"882_CR16","doi-asserted-by":"publisher","first-page":"5878","DOI":"10.1158\/0008-5472.CAN-08-0380","volume":"68","author":"ST Lee-Hoeflich","year":"2008","unstructured":"Lee-Hoeflich, S. T. et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878\u20135887 (2008).","journal-title":"Cancer Res."},{"key":"882_CR17","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1038\/s41388-021-01719-3","volume":"40","author":"M Berdiel-Acer","year":"2021","unstructured":"Berdiel-Acer, M. et al. Stromal NRG1 in luminal breast cancer defines pro-fibrotic and migratory cancer-associated fibroblasts. Oncogene 40, 2651\u20132666 (2021).","journal-title":"Oncogene"},{"key":"882_CR18","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","volume":"38","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z. et al. Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer. Cancer Cell 38, 279\u2013296 (2020).","journal-title":"Cancer Cell"},{"key":"882_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112533","volume":"42","author":"M Saini","year":"2023","unstructured":"Saini, M. et al. Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer. Cell Rep. 42, 112533 (2023).","journal-title":"Cell Rep."},{"key":"882_CR20","first-page":"3239","volume":"142","author":"JR Linnemann","year":"2015","unstructured":"Linnemann, J. R. et al. Quantification of regenerative potential in primary human mammary epithelial cells. Development 142, 3239\u20133251 (2015).","journal-title":"Development"},{"key":"882_CR21","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1074\/jbc.M608653200","volume":"282","author":"T Nagashima","year":"2007","unstructured":"Nagashima, T. et al. Quantitative transcriptional control of ERBB receptor signaling undergoes graded to biphasic response for cell differentiation. J. Biol. Chem. 282, 4045\u20134056 (2007).","journal-title":"J. Biol. Chem."},{"key":"882_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386 (2018).","journal-title":"Cell"},{"key":"882_CR23","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1038\/s41596-020-00474-1","volume":"16","author":"JF Dekkers","year":"2021","unstructured":"Dekkers, J. F. et al. Long-term culture, genetic manipulation and xenotransplantation of human normal and breast cancer organoids. Nat. Protoc. 16, 1936\u20131965 (2021).","journal-title":"Nat. Protoc."},{"key":"882_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.stem.2009.08.001","volume":"5","author":"Y Yoshida","year":"2009","unstructured":"Yoshida, Y., Takahashi, K., Okita, K., Ichisaka, T. & Yamanaka, S. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell 5, 237\u2013241 (2009).","journal-title":"Cell Stem Cell"},{"key":"882_CR25","doi-asserted-by":"crossref","unstructured":"Hlevnjak, M. et al. CATCH: a prospective precision oncology trial in metastatic breast cancer. JCO Precis Oncol. 5, PO.20.00248 (2021).","DOI":"10.1200\/PO.20.00248"},{"key":"882_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network.","year":"2012","unstructured":"Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"882_CR27","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2020.08.016","volume":"38","author":"S Ros","year":"2020","unstructured":"Ros, S. et al. Metabolic imaging detects resistance to PI3K\u03b1 inhibition mediated by persistent FOXM1 expression in ER+ breast cancer. Cancer Cell 38, 516\u2013533 (2020).","journal-title":"Cancer Cell"},{"key":"882_CR28","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1158\/1078-0432.CCR-20-3652","volume":"27","author":"P Narayan","year":"2021","unstructured":"Narayan, P. et al. FDA approval summary: alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer. Clin. Cancer Res. 27, 1842\u20131849 (2021).","journal-title":"Clin. Cancer Res."},{"key":"882_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96340-5","volume":"11","author":"A Osz","year":"2021","unstructured":"Osz, A., Lanczky, A. & Gyorffy, B. Survival analysis in breast cancer using proteomic data from four independent datasets. Sci. Rep. 11, 16787 (2021).","journal-title":"Sci. Rep."},{"key":"882_CR30","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","volume":"12","author":"Q Li","year":"2022","unstructured":"Li, Q. et al. INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors. Cancer Discov. 12, 356\u2013371 (2022).","journal-title":"Cancer Discov."},{"key":"882_CR31","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1158\/0008-5472.CAN-11-3034","volume":"72","author":"PR Gavine","year":"2012","unstructured":"Gavine, P. R. et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045\u20132056 (2012).","journal-title":"Cancer Res."},{"key":"882_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41571-019-0325-y","volume":"17","author":"P Sidaway","year":"2020","unstructured":"Sidaway, P. HER2-targeted agents overcome resistance. Nat. Rev. Clin. Oncol. 17, 133 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"882_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"882_CR34","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/s41586-021-03741-7","volume":"595","author":"H Jin","year":"2021","unstructured":"Jin, H. et al. EGFR activation limits the response of liver cancer to lenvatinib. Nature 595, 730\u2013734 (2021).","journal-title":"Nature"},{"key":"882_CR35","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s00432-021-03703-6","volume":"147","author":"A Prawira","year":"2021","unstructured":"Prawira, A., Le, T. B. U., Ho, R. Z. W. & Huynh, H. Upregulation of the ERBB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor. J. Cancer Res. Clin. Oncol. 147, 2955\u20132968 (2021).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"882_CR36","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.18632\/oncotarget.1866","volume":"5","author":"K Azuma","year":"2014","unstructured":"Azuma, K. et al. FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor. Oncotarget 5, 5908\u20135919 (2014).","journal-title":"Oncotarget"},{"key":"882_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3379","volume":"15","author":"A Issa","year":"2013","unstructured":"Issa, A. et al. Combinatorial targeting of FGF and ERBB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res. 15, R8 (2013).","journal-title":"Breast Cancer Res."},{"key":"882_CR38","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","volume":"23","author":"AB Hanker","year":"2017","unstructured":"Hanker, A. B. et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin. Cancer Res. 23, 4323\u20134334 (2017).","journal-title":"Clin. Cancer Res."},{"key":"882_CR39","first-page":"491","volume":"42","author":"AS Coetzee","year":"2023","unstructured":"Coetzee, A. S. et al. Nuclear FGFR1 promotes pancreatic stellate cell-driven invasion through up-regulation of neuregulin 1. Oncogene 42, 491\u2013500 (2023).","journal-title":"Oncogene"},{"key":"882_CR40","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","volume":"25","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto, Y. et al. A novel HER3-targeting antibody\u2013drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin. Cancer Res. 25, 7151\u20137161 (2019).","journal-title":"Clin. Cancer Res."},{"key":"882_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA Janne","year":"2022","unstructured":"Janne, P. A. et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 12, 74\u201389 (2022).","journal-title":"Cancer Discov."},{"key":"882_CR42","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.annonc.2023.05.004","volume":"34","author":"M Oliveira","year":"2023","unstructured":"Oliveira, M. et al. Patritumab deruxtecan in untreated hormone receptor-positive\/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study. Ann. Oncol. 34, 670\u2013680 (2023).","journal-title":"Ann. Oncol."},{"key":"882_CR43","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"882_CR44","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1093\/nar\/gkp581","volume":"37","author":"M Schmitt","year":"2009","unstructured":"Schmitt, M. & Pawlita, M. High-throughput detection and multiplex identification of cell contaminations. Nucleic Acids Res. 37, e119 (2009).","journal-title":"Nucleic Acids Res."},{"key":"882_CR45","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"882_CR46","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"882_CR47","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.2951","volume":"32","author":"D Heckl","year":"2014","unstructured":"Heckl, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR\u2013Cas9 genome editing. Nat. Biotechnol. 32, 941\u2013946 (2014).","journal-title":"Nat. Biotechnol."},{"key":"882_CR48","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/nprot.2013.143","volume":"8","author":"FA Ran","year":"2013","unstructured":"Ran, F. A. et al. Genome engineering using the CRISPR\u2013Cas9 system. Nat. Protoc. 8, 2281\u20132308 (2013).","journal-title":"Nat. Protoc."},{"key":"882_CR49","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nm.4038","volume":"22","author":"EM Noll","year":"2016","unstructured":"Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat. Med. 22, 278\u2013287 (2016).","journal-title":"Nat. Med."},{"key":"882_CR50","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/gcc.22431","volume":"56","author":"N Pfarr","year":"2017","unstructured":"Pfarr, N. et al. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance. Genes Chromosomes Cancer 56, 255\u2013265 (2017).","journal-title":"Genes Chromosomes Cancer"},{"key":"882_CR51","doi-asserted-by":"publisher","first-page":"9952","DOI":"10.18632\/oncotarget.2481","volume":"5","author":"M Kriegsmann","year":"2014","unstructured":"Kriegsmann, M. et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget 5, 9952\u20139965 (2014).","journal-title":"Oncotarget"},{"key":"882_CR52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.humpath.2018.03.018","volume":"77","author":"B Konukiewitz","year":"2018","unstructured":"Konukiewitz, B. et al. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum. Pathol. 77, 70\u201379 (2018).","journal-title":"Hum. Pathol."},{"key":"882_CR53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"882_CR54","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"882_CR55","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","volume":"31","author":"A Tarasov","year":"2015","unstructured":"Tarasov, A., Vilella, A. J., Cuppen, E., Nijman, I. J. & Prins, P. Sambamba: fast processing of NGS alignment formats. Bioinformatics 31, 2032\u20132034 (2015).","journal-title":"Bioinformatics"},{"key":"882_CR56","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"882_CR57","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"882_CR58","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/ncb3493","volume":"19","author":"L Velten","year":"2017","unstructured":"Velten, L. et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat. Cell Biol. 19, 271\u2013281 (2017).","journal-title":"Nat. Cell Biol."},{"key":"882_CR59","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34, 525\u2013527 (2016).","journal-title":"Nat. Biotechnol."},{"key":"882_CR60","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.12688\/f1000research.7563.1","volume":"4","author":"C Soneson","year":"2015","unstructured":"Soneson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences. F1000Res 4, 1521 (2015).","journal-title":"F1000Res"},{"key":"882_CR61","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","volume":"33","author":"DJ McCarthy","year":"2017","unstructured":"McCarthy, D. J., Campbell, K. R., Lun, A. T. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179\u20131186 (2017).","journal-title":"Bioinformatics"},{"key":"882_CR62","first-page":"2122","volume":"5","author":"AT Lun","year":"2016","unstructured":"Lun, A. T., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).","journal-title":"F1000Res"},{"key":"882_CR63","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nbt.4091","volume":"36","author":"L Haghverdi","year":"2018","unstructured":"Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421\u2013427 (2018).","journal-title":"Nat. Biotechnol."},{"key":"882_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.12688\/f1000research.16665.2","volume":"9","author":"M Garcia","year":"2020","unstructured":"Garcia, M. et al. Sarek: a portable workflow for whole-genome sequencing analysis of germline and somatic variants. F1000Res 9, 63 (2020).","journal-title":"F1000Res"},{"key":"882_CR65","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nbt.3820","volume":"35","author":"P Di Tommaso","year":"2017","unstructured":"Di Tommaso, P. et al. Nextflow enables reproducible computational workflows. Nat. Biotechnol. 35, 316\u2013319 (2017).","journal-title":"Nat. Biotechnol."},{"key":"882_CR66","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890 (2018).","journal-title":"Bioinformatics"},{"key":"882_CR67","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows\u2013Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"882_CR68","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics 32, 1220\u20131222 (2016).","journal-title":"Bioinformatics"},{"key":"882_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"882_CR70","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D. C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"882_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"882_CR72","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nprot.2017.016","volume":"12","author":"J Joung","year":"2017","unstructured":"Joung, J. et al. Genome-scale CRISPR\u2013Cas9 knockout and transcriptional activation screening. Nat. Protoc. 12, 828\u2013863 (2017).","journal-title":"Nat. Protoc."},{"key":"882_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-16193-9","volume":"7","author":"PN Spahn","year":"2017","unstructured":"Spahn, P. N. et al. PinAPL-Py: a comprehensive web-application for the analysis of CRISPR\/Cas9 screens. Sci. Rep. 7, 15854 (2017).","journal-title":"Sci. Rep."},{"key":"882_CR74","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1158\/2159-8290.CD-20-1202","volume":"11","author":"E Espinet","year":"2021","unstructured":"Espinet, E. et al. Aggressive PDACs show hypomethylation of repetitive elements and the execution of an intrinsic IFN program linked to a ductal cell of origin. Cancer Discov. 11, 638\u2013659 (2021).","journal-title":"Cancer Discov."},{"key":"882_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s43018-022-00355-4","volume":"3","author":"H Alborzinia","year":"2022","unstructured":"Alborzinia, H. et al. MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis. Nat. Cancer 3, 471\u2013485 (2022).","journal-title":"Nat. Cancer"}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00882-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00882-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T18:04:04Z","timestamp":1738173844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-024-00882-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["882"],"URL":"https:\/\/doi.org\/10.1038\/s43018-024-00882-2","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.T. and O.H. are employees of Miltenyi Biotec. Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM) has licensed the medium formulation to Miltenyi Biotec. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}